{"id":40519,"date":"2025-10-07T03:00:00","date_gmt":"2025-10-07T03:00:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/4789242_AE89242_0"},"modified":"2025-10-07T03:00:00","modified_gmt":"2025-10-07T03:00:00","slug":"japanese-innovation-comes-to-thailand-revolutionary-myopia-management-device-kubota-glass-debuts-at-asean-international-optics-fair-bangkok-2025","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=40519","title":{"rendered":"Japanese Innovation Comes to Thailand: Revolutionary Myopia Management Device Kubota Glass Debuts at ASEAN International Optics Fair Bangkok 2025"},"content":{"rendered":"
\n

TOKYO<\/span><\/span>, Oct. 7, 2025<\/span><\/span> \/PRNewswire\/ — Leading Japanese pharmaceutical company Kubota Pharmaceutical Holdings Co., Ltd. will introduce Thailand<\/span> to its groundbreaking myopia management device, Kubota Glass<\/b>, at Bangkok.<\/p>\n

\n

<\/a>
<\/span><\/p>\n<\/p><\/div>\n

Addressing Thailand’s<\/span> Growing Myopia Crisis<\/b><\/p>\n

Thailand<\/span> is facing a growing myopia challenge, with studies reporting that over 60<\/b>%*<\/b> of <\/b>young adults<\/b> are already myopic\u2014among the highest rates observed in Southeast Asia<\/span>. This pattern reflects the wider regional concern, where nearly half of the world’s population is projected to be myopic by 2050.<\/p>\n

“Thai families are increasingly concerned about their children’s vision health, especially with increased screen time from online learning,” said a company spokesperson. “Kubota Glass represents a breakthrough solution that could transform how Thai eye care professionals address childhood myopia.”<\/p>\n

Revolutionary Japanese AR Technology<\/b><\/p>\n

Kubota Glass employs proprietary AR X optical technology developed in Japan<\/span>, which projects actively stimulated defocus onto the retina to suppress myopia progression. The device requires only two hours of daily wear, making it highly practical for Thai children’s busy schedules while maintaining rigorous safety standards in compliance with ISO 15004-2 for ophthalmic instruments.<\/p>\n

Strong Early Clinical Results<\/b><\/p>\n

Small-scale pilot studies in the United States<\/span> and Taiwan<\/span> have shown encouraging preliminary results, including a high responder rate of up to 92%, with ongoing research continuing to evaluate the device’s long-term efficacy and safety profile.<\/p>\n

Key Features for Thai Market<\/b><\/p>\n